盈健醫療集團有限公司 01419Stock Information

Stock Information · Old Rules
// Company Overview //
Stock Name盈健醫療集團有限公司
Stock Code01419
Company Full Name盈健醫療集團有限公司
Industry醫療保健
Principal Activities主要在香港營運醫務中心。
Listing Date2016-04-01
Listing Rules EraOld Rules
Listing Rules ChapterNo data
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港九龍九龍灣常悅道3號企業廣場2期12樓
Business Address (Hong Kong)No data
Place of IncorporationNo data
Listing MethodNo data
Listing BoardMain Board
Websitehttp://www.humanhealth.com.hk
Share Registrar卓佳證券登記有限公司
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo data
// Offering Information //
Prospectus Date2016-03-17
Offer PriceHK$ 1.38 / shares
Total Funds RaisedHK$ 52,909,200
// Valuation & Financials //
Market Cap (at Offer Price)HK$ 0
// First Day Performance
First Day CloseLoading...
First Day OpenHK$ 1.85
First Day Change44.20%
First Day Volume180834000.0
First Day Turnover361008000.0
// Price Chart //
Loading...
// Use of Proceeds
Use of Proceeds1、約31.5百萬港元(相當于所得款項凈額的46.0%)將用于為在香港透過設立六間新專科醫務中心以擴充本集團的醫務中心網絡提供部分資金; 2、約4.8百萬港元(相當于所得款項凈額的7.0%)將用于為在香港透過設立六間新全科醫務中心擴充本集團的醫務中心網絡提供部分資金; 3、約10.3百萬港元(相當于所得款項凈額的15.0%)將用于為本集團擴充至中國市場提供部分資金; 4、約6.9百萬港元(相當于所得款項凈額的10.0%)將用于在香港收購已設立的醫務中心; 5、約4.1百萬港元(相當于所得款項凈額的6.0%)將用于在香港透過聘請品牌顧問、進行品牌建設活動及翻新及維護我們現有醫務中心以提升我們的品牌形象; 6、約4.1百萬港元(相當于所得款項凈額的6.0%)將用于提升我們的信息科技基建設施; 7、約6.9百萬港元(相當于所得款項凈額的10.0%)將用于營運資金及其他一般企業用途。
// Underwriting Syndicate //
独家保荐人 (1)
交银国际(亚洲)有限公司
整体协调人 (1)
交银国际证券有限公司
联席账簿管理人 (2)
交银国际证券有限公司 首控证券有限公司
联席牵头经办人 (4)
交银国际证券有限公司 首控证券有限公司 兴业金融证券有限公司 康证有限公司
// Cornerstone Investors //
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 首都医疗国际有限公司 34,011,480 HKD 7.04% 6 months 2016-10-01
// Directors & Management //
Chairman陳健平
Company Secretary文靜欣
No director data available.
// Major Shareholders //
Major Shareholders & Holdings陳健平及家族成員(68.29%);首都醫療國際有限公司(68.29%)
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. Some data is supplemented from HKEX New Listing Reports ([HKEX]). All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics